Introduction
Interleukin (IL)-27 is a heterodimeric cytokine belonging to the IL-12 family, 1 which is produced by antigen-presenting cells and functions on different cell types expressing the full receptor (R) complex. [2] [3] [4] [5] [6] The IL-27R contains the unique receptor subunit WSX-1, paired with the gp130 chain; both chains are necessary for IL-27 signaling. 7, 8 IL-27 exerts antitumor activity in different tumors through indirect 5, [9] [10] [11] and direct mechanisms. 12, 13 Furthermore, functional screenings of genes expressed in acute myeloid leukemia cells revealed that the IL-27R possesses hematopoietic cell-transforming properties, 14 but no information is available on the role of IL-27/IL-27R in pediatric acute lymphoblastic leukemias.
B-acute lymphoblastic leukemia (B-ALL) is the most common pediatric hematological cancer that derives from aberrant expansion of early B lymphocytes in the BM. 15 The outcome for children with B-ALL has improved significantly with current therapies, resulting in event-free survival exceeding 75% for most patients. 15 However, a considerable number of B-ALL patients still relapse, highlighting the need for novel therapies. In this respect, several studies showed that the bulk B-ALL arise from a small population of tumor-initiating cells (TICs) that proliferate slowly, thus being unresponsive to conventional cytotoxic therapies that target predominantly highly proliferating cells. Thus, therapeutic eradication of B-ALL-initiating cells together with the blast leukemic cells is essential for the definitive cure of this disease. Moreover, it has been proposed that tumor cell population displays a phenotypic plasticity between TICs and non-TICs. 16 Thus, a dynamic equilibrium may exist between TICs and non-TICs within a tumor, but may be shifted in one direction or another by different microenvironmental stimuli that influence the probability of interconversion between the TICs and non-TICs compartments. 16 Taken together, optimal therapeutic approaches will need to incorporate agents that target both TICs and non-TICs.
With this background, we asked whether IL-27 functions as an antitumor agent against B-ALL using a preclinical model in which TICs may engraft. To this end, NOD/SCIDIl2rg À/À (NSG) mice were injected with B-ALL cells obtained from BM pediatric patients and treated with IL-27 or phosphate buffered saline (PBS). On the basis of previous studies, 17 TICs were identified as CD133 þ CD19 À cells, as this population (1) was the only one within the whole B-ALL tumor that could self-renew to engraft serial SCID/NOD recipients, 17 (2) differentiates in vivo to produce leukemias with similar immunophenotypic and karyotypic features similar to those detected in primary tumor samples 17 and (3) was more resistant to treatment with dexamethasone and vincristine, 17 key components in childhood ALL therapy, than the bulk leukemia population.
Materials and methods

Patient samples
BM aspirates from four pro-B, 19 early pre-B and six pre-B pediatric ALL patients were obtained for diagnostic purpose at disease onset following informed consent from children's parents or their legal guardians. The important demographic, immunological and cytogenetic features (Supplementary Materials and Methods) of the patients are shown in Table 1 . All patients included in this study were at the stage of diagnosis and were untreated. Aliquots of BM aspirates for diagnostic purposes from 12 age-matched individuals not affected by oncological disorders were obtained following informed consent. This study design was approved by the Ethics Committee of the University of Padova, Padova, Italy and by the Ethics Committee of the G. Gaslini Institute, Genova, Italy. Mononuclear cell suspensions of BM cells were isolated on Ficoll-Hypaque density gradients and frozen in liquid nitrogen until tested. Unfractionated B-ALL cell suspensions containing 490% blasts were used for in vivo experiments. In vitro studies were conducted using CD19 þ cells purified by immunomagnetic beads coated with anti-human CD19 monoclonal antibody (mAb; Miltenyi Biotec, Gladbach, Germany). Immunophenotypic characterization of B-ALL cells was carried out as described. 18 TICs were identified as CD133 þ CD19 À cells, as reported. 17 Normal pro-B, early pre-and pre-B cells were identified as
Cell culture, antibodies, reagents and flow cytometry Human recombinant IL-27 and mouse immunoglobulin G2b anti-human WSX1 were purchased from R&D Systems, Inc. (Minneapolis, MN, USA). The concentrations of IL-27 tested in vitro ranged from 10 to 200 ng/ml. In some experiments, human cells were isolated from murine tissues by immunomagnetic beads coated with anti-human CD45 mAb (Miltenyi Biotec), according to the manufacturer's protocol. Fluorochrome-conjugated CD45, CD10, CD19, CD38 and CD20 mAbs were obtained from BD Biosciences (San Josè, CA, USA). Fluorochrome-conjugated anti-human CD133 (clone AC133) was obtained from Miltenyi Biotech. FITC-conjugated antihuman Ki67 mAbs were obtained from Dako, Glostrup, DenmarK. PE-conjugated goat anti-mouse immunoglobulin G2b was obtained from Caltag, Burlingame, CA, USA. Isotype-matched antibodies of irrelevant specificity (Caltag) were used as controls. Cells were scored using a FACSCalibur analyzer (BD Biosciences) and data processed using CellQuest software 3.0 (BD Biosciences).
Cell proliferation and apoptosis assays
Eight CD19
þ purified B-ALL cell fractions (patients (Pt) 1, 2, 7, 10, 20, 21, 28 and 29) were cultured for 6, 24, 48 and 72 h with or without 50 ng/ml IL-27, following titration experiments. Cells were then stained intracellularly with anti-Ki67 mAb using the cytofix/cytoperm kit (BD Biosciences) and analyzed by flow cytometry. Apoptosis was assessed using the rhAnnexin V/FITC kit from Immunostep S.I., Salamanca, Spain. 
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Chorioallantoic membrane (CAM) assay CAM assay was performed as reported, 19 and loaded with the following: 1 ml of PBS (negative control); 1 ml of PBS with 250 ng vascular endothelial growth factor (R&D Systems) as positive control; 1 ml of medium from purified CD19 þ B-ALL cells from patients (Pt 4, 5, 13, 23 and 26) cultured for 48 h with or without IL-27; and 1 ml of medium containing IL-27. All supernatants were tested in triplicate and means±s.d. were calculated. CAMs were examined daily until day 12 and photographed in ovo with a stereomicroscope equipped with a camera and image analyzer system (Olympus Italia, Milano, Italy). On day 12, the angiogenic response was evaluated by the image analyzer system as the number of vessels converging toward the sponges.
In some experiments, CAMs were treated on day 8 with sponges loaded with 1 ml of medium from CD19 þ B-ALL cells treated with IL-27 (Pt 4, 5 and 23) alone or containing 2.5 mg/ml of an anti-human tissue inhibitor of metalloproteinases (TIMP)-2 mAb (R&D System) or 0.5 mg/ml of an anti-human interferon (IFN)-g mAb (EBiosciences, San Diego, CA, USA). Appropriate isotype-matched mAbs were used as controls.
Mice studies
NSG mice aged 4-6 weeks were purchased from (Jackson Laboratory, Bar Harbor, ME, USA) were housed under specific pathogen-free conditions. All procedures involving animals were performed in the respect of the National and International current regulations (D.l.vo 27/01/1992, n.116, European Economic Community Council Directive 86/609, OJL 358, 1 December 1987). Two groups of five animals each were injected i.v. with 2 Â 10 6 unfractionated BM-B-ALL cell suspension from six pediatric patients (3, 9, 15, 16, 17 and 18) . These samples were selected as they were highly infiltrated with neoplastic cells (490%) that highly expressed WSX-1 (at least
. One group of mice was treated with two doses per week of human recombinantIL-27 (1 mg/mouse/dose) starting from 3 days after injection of tumor cells. The other group was injected with PBS (controls) following the same time schedule. Mice were killed when signs of poor health became evident. The following tissues were collected from each animal: spleen, PB from the retro-orbital vein, and BM obtained from flushing of both femurs. Serial transplantations were performed by injection of 0.5-1 Â 10 6 human CD45 þ cells purified from BM of control mice as follows: (1) 
Morphological and histochemical analyses
Tissue samples were fixed in 4% neutral buffered formalin, embedded in paraffin, sectioned at 4 mm and stained with hematoxylin and eosin. Silver impregnation was performed using the 'Silver Impregnation For Reticulum Staining 04-040801 Kit' (Bio-Optica Milano S.p.A, Milan, Italy), on paraffin-embedded sections according to the manufacturer's instructions.
Reverse transcription PCR
RNA was extracted using the RNeasy Mini kit from Qiagen GmbH (Hilden, Germany) from unfractionated B-ALL cell samples at diagnosis (Pt 3 and 5) and from human CD45 þ cells purified from the spleen of mice injected with cells from Pt 3 or 5. Human glyceraldehyde 3-phosphate dehydrogenase and CD19 gene expression was investigated by reverse transcription PCR using specific set of primers, as described. 20 
PCR array and real-time PCR
The total RNA was extracted from (1) CD19 þ B-ALL cells from five patients (Pt 4, 5, 13, 23 and 26) cultured for 24 h with or without IL-27 and (2) CD45 þ B-ALL cells purified from spleens (n ¼ 2) and BM (n ¼ 1) of mice injected i.v. with B-ALL cells (Pt 3 and 15) and treated with PBS or human recombinantIL-27, using Trizol (Invitrogen, Camarillo, CA, USA). RNA (1 mg) was reverse transcribed using the RT 2 mRNA First strand Kit purchased from (SABioscience, Frederick, MD, USA). Mature micro-RNAs (miRNAs) were isolated using RT 2 qPCR-Grade miRNA isolation kit and reverse transcribed using the RT 2 miRNA First strand Kit (SABioscience). Human Cancer miRNA RT 2 Profiler PCR Array (which allows to detect the expression of 84 cancer-related miRNAs), Human Angiogenesis RT 2 Profiler PCR Array, RT 2 Real-Timer SyBR Green/ROX PCR Mix, miR-U6 and miR-155 primer sets were purchased from SABiosciences. PCR was performed on an ABI Prism 7700 Sequence Detector (Applied Biosystems, Foster City, CA, USA). For data analysis, the DDC t method was used: in PCR array experiments, for each gene, fold changes were calculated as difference in miRNA or gene expression between leukemic cells cultured with or without IL-27. According to the instructions of the manufacturer, a significant threshold is defined as a fourfold change in gene expression corresponding to Po0.001; expression of miR-155 in explanted CD45
þ B-ALL cells was normalized to U6 housekeeping miRNA and expressed relative to a calibrator sample as positive control (primary B-ALL cells before injection).
Statistical methods
Results were analyzed by Graph Pad Prism software (GraphPad Software Inc., La Jolla, CA, USA), calculated with 99% confidence interval and were two sided. Data were analyzed using Student's t-test for the analysis of the results of the CAM assay or Mann-Whitney test for the analysis of CD45 þ cells harvested from the different animal tissues. A P-value o0.05 was considered statistically significant.
Results
Expression of IL-27R in pediatric B-ALL cells and in their normal counterparts
WSX-1 expression was investigated in 29 B-ALL cell samples from BM pediatric patients and their normal counterparts (n ¼ 12). Four-color staining of normal BM mononuclear cells for CD19, CD10, CD20 and WSX-1 showed that WSX-1 was expressed in normal pro-B, early pre-B and pre-B cells (percentages are shown in Figure 1a , three representative experiments in Figure 1b) . Figure 2a shows the expression in one representative pro-B (left panel, median 65.5%, range 33-83%), one early pre-B (middle panel, median 54%, range 23-94%) and one pre-B ALL cell sample (right panel, median 66.5%, range 49-83%). Table 1 reports percentages of WSX-1 expression in each individual patient. The other IL-27R chain, namely gp130, was expressed in normal and neoplastic B cells (not shown), thus indicating that IL-27 may function on these cells. Finally, statistical analysis showed that WSX-1 expression in neoplastic B-ALL cell samples (n ¼ 29) was significantly (Po0.0001) higher as compared with that of normal early B-cell samples (n ¼ 12).
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IL-27 antitumor activity in vitro against pediatric B-ALL cells
The IL-27 antitumor activity against pediatric B-ALL cells was tested in vitro in terms of modulation of cell proliferation, apoptosis and angiogenic activity. First, CD19
þ cells purified from eight B-ALL cell samples (Pt 1, 2, 7, 10, 20, 21, 28 and 29) were cultured for 6-72 h with or without IL-27 at different concentrations (range 10-200 ng/ml). IL-27 treatment (50 ng/ml) for 72 h significantly increased (P ¼ 0.00021) the percentage of apoptotic cells (Figure 2b) , and significantly inhibited (P ¼ 0.0254) B-ALL cell proliferation (Figure 2c) . A 6 to 48-h treatment with IL-27 at concentrations o50 ng/ml did not significantly affect B-ALL cell survival (Figure 2b , dot plots on the right) or proliferation (Figure 2c , histograms on the right). IL-27 at concentrations of 100 and 200 ng/ml yielded results similar to those observed using 50 ng/ml IL-27 ( Figures  2b and c) .
The angiogenic activity of five CD19 þ purified from B-ALL cell suspensions (Pt 4, 5, 13, 23 and 26) cultured for 48 h with or without 50 ng/ml of IL-27 was investigated using the in vivo CAM system. CAM treated with sponges loaded with vascular endothelial growth factor (positive control) or with supernatants from B-ALL cells were surrounded by allantoic vessels that developed radially toward the implant in a 'spoked-wheel' pattern. In the representative experiment shown in Figure 2d , left upper panel, the mean number of vessels formed in the To prove unambiguously that IFN-g and TIMP-2 were the major mediators of the angiostatic activity exerted by IL-27, we tested the angiogenic activity of IL-27-treated CD19
þ B-ALL cell supernatants (Pt 4, 5 and 23) following incubation with neutralizing antibodies to human IFN-g and TIMP-2. As shown in Figure 2d Finally, we tested the ability of IL-27 to modulate the expression of a set of miRNA implicated in human tumorigenesis. [21] [22] [23] These experiments showed that IL-27 treatment caused downregulation of miR-155 in all B-ALL cell samples tested (5 to 13.5-fold, Figure 2e) . Downregulation of miR301, 222 and let7e and upregulation of miR212 and 148b was also observed in two or three samples (not shown), whereas all the other cancerrelated miRNAs included in the PCR array kit were not significantly modulated (not shown).
IL-27 inhibited B-ALL cell spreading in NSG mice
The direct antitumor activity of IL-27 against primary B-ALL cells was tested in vivo in NSG mice, which represent the most suitable model for efficient engraftment of primary neoplastic cells and TICs. [24] [25] [26] Thus, six early pre (CD19 þ CD10 þ ) B-ALL cell suspensions (Pt 3, 9, 15, 16, 17 and 18) were injected i.v. in two groups of five animals each (controls and IL-27-treated mice) and killed 6-8 weeks later when signs of poor health became evident in controls. Human cells were identified using the human CD45 surface marker, in association with CD10 and CD19. B-ALL cells efficiently engrafted in all control and treated mice, as witnessed by the presence of at least 1% human CD45 þ cells in murine PB, BM and spleens. Flow-cytometric analysis showed that all engrafted cells from both groups of mice coexpressed CD45 and CD10 (Figure 3a) , but lacked CD19 expression (see below). The presence of human CD45 þ CD10 þ cells were significantly reduced by IL-27 treatment in PB (P ¼ 0.0002), BM (Po0.0001) and spleens (P ¼ 0.0004; Figure 3b ). Data on percentages of human CD45 þ cells detected in PB, BM and spleens from controls and IL-27-treated mice are reported in Table 2 .
To gain more insight into the mechanisms underlying the absence of expression of the CD19 marker in engrafted neoplastic cells (Figures 3c and d) , reverse transcriptionPCR was performed on CD45 þ cells purified from the spleen of two control animals injected with B-ALL cells from Pt 3 and 5, respectively. CD19 gene expression was investigated in comparison on B-ALL cells from Pt 3 and 5 at diagnosis. These experiments showed that CD19 mRNA was expressed in the original B-ALL cell samples but not in human CD45 þ cells harvested from animals. This finding suggests that cells of human origin that are able to engraft and expand into mice are CD45 þ CD19 À or, alternatively, that they may engraft the CD45 þ CD19 þ population that lack CD19 surface expression through mechanisms occurring at the transcriptional level ( Figure 3e) .
Next, we asked whether IL-27 in our preclinical model may affect the putative TIC compartment, identified as the CD133 þ CD19 À leukemia population. 17 To this end, the presence of putative TICs was investigated by flow cytometry in B-ALL cell suspensions at diagnosis (Pt 3, 9, 15, 16, 17 and 18) and after injection into mice. Thus, PB, BM and spleens collected from controls and IL-27-treated animals, used in the abovedescribed experiments, were analyzed. The CD133 þ CD19
À population was present in all B-ALL samples at diagnosis (mean Abbreviations: BM, bone marrow; IL-27, interleukin-27; PB, peripheral blood.
IL-27 and pediatric B-ALL S Canale et al percentage 4.4, range from 2.3 to 10, not shown) and expressed WSX-1 (Figure 4a ), indicating that TICs may be targeted by IL-27. As shown in Figure 4b , TICs were consistently found in PB, spleen and BM from control mice and significantly reduced by IL-27 treatment in PB (P ¼ 0.0001), spleen (P ¼ 0.0161) and BM (P ¼ 0.0017). Percentages of CD133 þ CD19 À cells in PB, spleens and BM from controls and treated mice are reported in Table 2 . Furthermore, human CD45 þ cells purified from BM of primary recipients (injected with B-ALL cells from Pt 16 or 17 or 18) re-grew in secondary recipients, in which they maintained the same phenotype expressed in primary hosts (Figure 4c and for comparison Figure 3c ) and the same Ig and T-cell receptor (TCR) rearrangements (Supplementary Materials and Methods) as those detected in the original B-ALL sample at diagnosis (Figure 4d ), indicating that B-ALL cells before and after injection into NSG mice belonged to the same clone.
Morphological and histochemical analyses of spleens harvested from control and IL-27-treated animals showed that injection of leukemic cells in NSG mice gave rise to small tumor masses localized in the spleen and formed by lymphoid cells endowed with a large clear cytoplasm that differ from the murine splenocytes (Figure 5aA ). Silver impregnation showed that these lymphoid masses contained a well-developed reticulum fiber network (Figure 5aB ) that appeared to be shaped to intratumoral microvascularization. 27, 28 The treatment with IL-27 reduced the growth of these lymphoid masses (Figure 5aC ), which showed a very weak reticulum fiber network (Figure 5aD) . Finally, reverse transcription-PCR experiments using CD45 þ cells purified from the spleen and BM of controls and treated mice showed that, consistent with in vitro results, IL-27 strongly reduced miR-155 mRNA in vivo (Figure 5b ). þ cells purified from the spleen of one control primary and from one secondary recipient is shown. Positive control ¼ DNA of PB lymphocytes from B-ALL cell samples at diagnosis (provided by Professor G Basso) that showed the TCR:Vg9Jg1.3 or IgH:VH3JH rearrangements; negative control ¼ DNA of PB lymphocytes from healthy donors; MW, molecular weight marker VIII.
Discussion
B-ALL is the most frequent malignancy of childhood. Despite its overall good response to current treatment protocols, 29 there is great demand for new therapies for high-risk and relapsed patients. In this context, the existence of leukemia-initiating cells greatly attracted interest as they may provide a key target for novel curative therapies. The presence of leukemic stem cells has been clearly defined in acute myeloid leukemia by xenotransplantation studies 30 and recently reported for pediatric B-ALL. 17 In this study, we asked whether IL-27 acts as antitumor agent against pediatric B-ALL cells in a preclinical model represented by NSG mice, which represents the most suitable recipient for engraftment of primary tumors and TICs. 24 Furthermore, the BM microenvironment appears to be sufficiently conserved between mice and men to allow survival and proliferation of leukemic human stem cell populations that cannot be maintained in vitro. 31 This animal model allowed us to show that IL-27 strongly reduced the presence of leukemic cells in the PB and inhibited leukemic spreading in BM and spleen. Engrafted cells unambiguously derived from the original B-ALL cell samples, as witnessed by the presence of the same IgH and TCR rearrangements. However, immunophenotypic analysis showed that engrafted B-ALL cells, compared with the original sample, maintained CD45 and CD10, but not CD19 expression. The mechanism underlying the absence of CD19 surface expression in engrafted human cells may be ascribed to posttranscriptional events, as described 26 and/or related to their acquisition of a more immature phenotype possibly induced by microenvironmental conditions. In addition, it was suggested that ETV6-RUNX1-positive cells capable of reconstituting leukemia upon transplantation to NOD-SCID mice have the CD19 À phenotype. 32 The inhibition of B-ALL cell spreading is likely related to the ability of IL-27 to function directly against tumor cell through inhibition of cell proliferation and angiogenesis, and induction of apoptosis, as supported by our in vitro results. Furthermore, we showed that IL-27 downregulated miR-155 in B-ALL cells. MiR-155 has been reported to be expressed in activated B lymphocytes, 33 to be regulated in the course of immune responses 33 and to accumulate in human B-cell lymphomas. [34] [35] [36] In addition, studies on transgenic mice showed that miR-155 has a role in inducing a polyclonal expansion of preleukemic pre-B cells favoring the acquisition of secondary genetic changes for full transformation. 37 However, the mechanisms by which miR155 functions as a putative oncomiR are largely unknown.
Our results support the concept that IL-27 may represent a new anti-leukemic drug to be tested in future clinical trials, as this cytokine may target B-ALL blasts and putative TICs and inhibit the leukemic cell spreading. In this respect, it was shown that IL-27 enhances proliferation and differentiation of human CD34 þ cells. 38 These findings, supported by our results that normal early B cells expressed complete IL-27R, suggest that this cytokine may induce early stages of differentiation in normal hematopoietic stem cells, highly compromised in leukemic patients. An additional argument in favor of our proposal is the low toxicity shown by IL-27 in animal models, likely in relation to the low induction of IFN-g in vivo.
9 Finally, simultaneous activation of in vivo antitumor effector mechanisms mediated by cytotoxic T lymphocytes , natural killer and CD8 þ T cells may be induced by IL-27. 1 
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